Conclusion: This is the first pan-European retrospective registry for AIP. It will produce the first large-scale data on treatment of European patients with AIP, providing answers on the use and effectiveness of treatment regimens. In the future, this collaboration may provide a network for continuation into a prospective European registry.
Purpose
Adjuvant chemotherapy for colon cancer with lymph node involvement (Stage III) has been the standard of care since the 1990s. Meanwhile, considerable evolvement of surgery combined with dedicated histopathological examinations may have led to stage migration. Furthermore, prognostic factors other than lymph node involvement have proven to affect overall survival. Thus, adjuvant chemotherapy in Stage III colon cancer should be reconsidered. The objective was to compare recurrence rates and survival in stage III colon cancer patients treated with or without adjuvant chemotherapy. Further, to assess the impact of extensive mesenterectomy, lymph node stage and vascular invasion on outcome.
Methods
Consecutive patients operated for Stage III colon carcinoma between 31 December 2005 and 31 December 2015 were identified in the pathological code register by matching colon (T67) and either adenocarcinoma (M81403) or mucinous adenocarcinoma (M84803), with lymph node (T08) and metastasis of adenocarcinoma (M81406 or M84806). Medical records of all identified patients were reviewed.
Results
Of 216 identified patients, 69 received no postoperative adjuvant chemotherapy (group NC), 69 insufficient adjuvant chemotherapy (FLV or < minimum recommended 6 cycles FLOX, group IC), and 78 sufficient adjuvant chemotherapy (≥ 6 cycles FLOX, group SC). When adjusted for age and comorbidity, 5-year overall survival did not differ statistically significant between groups (76% vs. 83% vs. 85%, respectively). Vascular invasion and a high lymph node ratio significantly reduced overall survival.
Conclusion
The findings imply that subgroups of Stage III colon cancer patients have good prognosis also without adjuvant chemotherapy. For definite conclusions about necessity of adjuvant chemotherapy, prospective trials are needed.
Airazat M. Kazaryan er ph.d., legespesialist ved Gastrokirurgisk seksjon, Sykehuset Østfold og overlege ved Kirurgisk avdeling, Helse Fonna, Odda. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Lars L. Eftang er ph.d. og overlege ved Gastrokirurgisk avdeling, Akershus universitetssykehus. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Pål Ødegaard er lege i spesialisering del 2 ved Kirurgisk avdeling, Sykehuset Østfold. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Martin Hagve er lege i spesialisering del 3 ved Gastrokirurgisk avdeling, Universitetssykehuset Nord-Norge og førsteamanuensis ved UiT Norges arktiske universitet. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Benedicte Skjold-Ødegaard er overlege ved Gastrokirurgisk seksjon, Helse Fonna, Haugesund. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Ole Christian Olsen er overlege ved Kirurgisk avdeling, Vestre Viken, Drammen. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Svetlana A. Sharapova er overlege ved Kirurgisk avdeling, Sykehuset Innlandet, Hamar. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.Rafael Georg Breuer er konstituert overlege ved Gastrokirurgisk seksjon, Sørlandet sykehus i Kristiansand og i Arendal. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.